about
Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort studyInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceQuantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus InfectionAssignment of genes for interleukin-8 receptors (IL8R) A and B to human chromosome band 2q35Per-event probability of hepatitis C infection during sharing of injecting equipmentThe Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?Understanding the complex evolution of rapidly mutating viruses with deep sequencing: Beyond the analysis of viral diversity.Occult infection with hepatitis C virus: friend or foe?Fatigue: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal studyIncidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohortEvidence that hepatitis C virus genome partly controls infection outcome.A bioinformatics pipeline for the analyses of viral escape dynamics and host immune responses during an infectionCharacteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis CBalance of pro- and anti-inflammatory cytokines correlates with outcome of acute experimental Pseudomonas aeruginosa keratitis.Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.Estimating progression to cirrhosis in chronic hepatitis C virus infection.Reduced cardiac vagal modulation impacts on cognitive performance in chronic fatigue syndromeMulticentric Castleman's disease treated with antivirals and immunosuppressants.Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression ratesDynamics of HCV RNA levels during acute hepatitis C virus infection.Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyAre chronic fatigue and chronic fatigue syndrome valid clinical entities across countries and health-care settings?Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.Acute Q fever and brachial neuritis: case report and literature review.Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression.Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionA descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners.Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.Acquiring hepatitis C in prison: the social organisation of injecting risk.Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012.If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer.CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease.Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection
P50
Q24676579-1BB81F3C-A12E-4F4A-AA11-448BF3331F42Q26783056-93B8F397-E65B-48DB-B7BD-5E24564FCFE5Q27473054-4580DF16-3095-4F56-AA14-DC0B706DEC76Q27490862-FD6D2ED4-9169-4BE1-8662-E5E6EFB9D48EQ28269514-AC3FDCC3-3190-4963-8D63-280162228A06Q28540414-8E669C1D-F6CA-4B33-AF47-303C55E9175DQ28553969-F8B3A717-1EC1-43A7-B848-C54B0288F2AEQ30240629-D4AAD8D8-1D8A-4772-83A8-F49B816B0338Q30416187-64CE6E48-0F70-485C-BCB1-C644ED78AED6Q31107779-15B9AF09-E0D8-4EE1-B650-A0ADB804EB7EQ33259666-EFC8E5F4-CBAE-471F-82B0-4037C2D3E2C5Q33724826-359AD6F2-0024-4EF7-85F7-0488DA7A5B82Q33746744-D047C0B9-98DF-4796-BA57-466E11EE4905Q33810826-E01104C6-52A0-4421-8830-691F08522D2EQ33955516-75E5D61A-F288-4C1B-A9F8-522D3D798887Q34120660-CD0AB62D-0804-46D2-B15B-FAB13706EDF0Q34164063-13D381CD-D221-4FC1-8681-CAAF0865B2FAQ34176146-3EED4CE2-F62B-44CE-BDE5-539634A6D3F5Q34204254-517BA872-3944-49CB-BD14-7C1E61BB6DF0Q34389608-A43DF909-3FC4-4741-A018-C6FF3D2D424DQ34482454-3D92E581-F613-499A-815A-40BBD64DB3E7Q34536870-77A2CE5F-D75A-4072-9C4B-32DC682F801DQ34714349-D2F2047B-5D91-41C0-A5A1-F8EDEDD7B9E8Q34763459-946EB3D6-5012-41AC-A8C2-6304CF609603Q34771346-B8252DC1-9C59-4E6C-8B49-3878A7B4B9CEQ34777709-B1FF703B-8E89-4B02-A0A7-0828BBECA7EAQ34785317-64BE20E4-3974-4D36-B0FD-8EE665161C18Q34904841-75D8BD4B-8374-4920-A7E2-F596951CB035Q35019909-31A99953-D8E6-405B-959E-80D9A98D3780Q35023885-8A5E513F-A70D-421C-91B4-A8ECCB8B8C4DQ35044131-73BB0C77-69BD-4F04-9E29-65D20D1EC50CQ35053399-2AC8F4B4-D577-46A8-9C0F-D468B8273F01Q35105946-69F20B58-559E-4D41-89A2-7650A53F0BC8Q35249648-668BB87B-A2FA-4D7A-A908-9B382610A1D8Q35549941-71B842A4-816B-4801-87B7-AA5191585D29Q35551683-53FCF304-B228-49F0-9592-6E2322369D2CQ35584799-DE420497-BD9D-44F7-B218-AB68D8C3B095Q35596811-70CCD983-905B-4ABB-B2A1-C284BFDAE5A9Q35635848-B5EDEAA5-BD79-474E-A30B-1B8FCF2642D1Q35641523-F57944C5-EEEC-4CA2-BFF4-AACF7A07EA9A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew R. Lloyd
@ast
Andrew R. Lloyd
@en
Andrew R. Lloyd
@es
Andrew R. Lloyd
@nl
Andrew R. Lloyd
@sl
type
label
Andrew R. Lloyd
@ast
Andrew R. Lloyd
@en
Andrew R. Lloyd
@es
Andrew R. Lloyd
@nl
Andrew R. Lloyd
@sl
prefLabel
Andrew R. Lloyd
@ast
Andrew R. Lloyd
@en
Andrew R. Lloyd
@es
Andrew R. Lloyd
@nl
Andrew R. Lloyd
@sl
P106
P1153
56962782100
P21
P31
P496
0000-0001-6277-8887